Da Wei Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Da Wei Huang has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- George W. Wright
Biometric Research Branch, Division of Cancer Diagnosis and Treatment, National Cancer Institute, National Institutes of Health, Bethesda, MD
16 shared publications - Jagan Muppidi
Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
16 shared publications - James D. Phelan
Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
16 shared publications - Arnold Bolomsky
National Cancer Institute 1 Lymphoid Malignancies Branch, Center for Cancer Research , Bethesda, Maryland
15 shared publications - Björn Häupl
University Hospital Frankfurt 3 Department of Medicine, Hematology and Oncology Goethe University Frankfurt, Frankfurt am Main, Germany
15 shared publications - Boya Wang
Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
15 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Supplemental Figure 1. IRF4-GFP knock-in reporter cell lines. Supplemental Figure 2. IRF4-GFP CRISPR screen in adult T-cell lymphoma and screen controls. Supplemental Figure 3. The OST is essential for DLBCL. Supplemental Figure 4. The role of the OST complex in radiation chimeras. Supplemental Figure 5. The B-cell receptor is glycosylated by the OST complex. Supplemental Figure 6. B-cell receptor deglycosylation leads to higher surface expression. Supplemental Figure 7. B-cell receptor deglycosylation leads to signaling changes in proximal BCR signaling components. Supplemental Figure 8. BCR deglycosylation leads to recruitment of CD22 on the cell surface to the BCR and signaling alterations in GCB DLBCL. Supplemental Figure 9. BCR internalization and My-T-BCR formation in glycosylation deficient cells. Supplemental Figure 10. NGI-1 synergizes with BTK and PI3K inhibitors.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Supplemental Figure 1. IRF4-GFP knock-in reporter cell lines. Supplemental Figure 2. IRF4-GFP CRISPR screen in adult T-cell lymphoma and screen controls. Supplemental Figure 3. The OST is essential for DLBCL. Supplemental Figure 4. The role of the OST complex in radiation chimeras. Supplemental Figure 5. The B-cell receptor is glycosylated by the OST complex. Supplemental Figure 6. B-cell receptor deglycosylation leads to higher surface expression. Supplemental Figure 7. B-cell receptor deglycosylation leads to signaling changes in proximal BCR signaling components. Supplemental Figure 8. BCR deglycosylation leads to recruitment of CD22 on the cell surface to the BCR and signaling alterations in GCB DLBCL. Supplemental Figure 9. BCR internalization and My-T-BCR formation in glycosylation deficient cells. Supplemental Figure 10. NGI-1 synergizes with BTK and PI3K inhibitors.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normalized Read Counts of CRISPR screens. Table S5. CRISPR screen score of essentiality screens. Table S6. Glycoproteomics after NGI-1 treatment. Table S7.HBL1 and TMD8 Phosphotyrosone Phosphoproteome (pYome). Table S8. TMD8 CD79A-BioID. Table S9. HBL1 CD22 BioID. Table S10. Brunello library sgRNA normalized read counts of NGI-1 drug modified screen (TMD8). Table S11. CRISPR screen score of NGI-1 drug modifier screen. Table S12. TMD8 Drug screen Excess HSA.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normalized Read Counts of CRISPR screens. Table S5. CRISPR screen score of essentiality screens. Table S6. Glycoproteomics after NGI-1 treatment. Table S7.HBL1 and TMD8 Phosphotyrosone Phosphoproteome (pYome). Table S8. TMD8 CD79A-BioID. Table S9. HBL1 CD22 BioID. Table S10. Brunello library sgRNA normalized read counts of NGI-1 drug modified screen (TMD8). Table S11. CRISPR screen score of NGI-1 drug modifier screen. Table S12. TMD8 Drug screen Excess HSA.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normalized Read Counts of CRISPR screens. Table S5. CRISPR screen score of essentiality screens. Table S6. Glycoproteomics after NGI-1 treatment. Table S7.HBL1 and TMD8 Phosphotyrosone Phosphoproteome (pYome). Table S8. TMD8 CD79A-BioID. Table S9. HBL1 CD22 BioID. Table S10. Brunello library sgRNA normalized read counts of NGI-1 drug modified screen (TMD8). Table S11. CRISPR screen score of NGI-1 drug modifier screen. Table S12. TMD8 Drug screen Excess HSA.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normalized Read Counts of CRISPR screens. Table S5. CRISPR screen score of essentiality screens. Table S6. Glycoproteomics after NGI-1 treatment. Table S7.HBL1 and TMD8 Phosphotyrosone Phosphoproteome (pYome). Table S8. TMD8 CD79A-BioID. Table S9. HBL1 CD22 BioID. Table S10. Brunello library sgRNA normalized read counts of NGI-1 drug modified screen (TMD8). Table S11. CRISPR screen score of NGI-1 drug modifier screen. Table S12. TMD8 Drug screen Excess HSA.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normalized Read Counts of CRISPR screens. Table S5. CRISPR screen score of essentiality screens. Table S6. Glycoproteomics after NGI-1 treatment. Table S7.HBL1 and TMD8 Phosphotyrosone Phosphoproteome (pYome). Table S8. TMD8 CD79A-BioID. Table S9. HBL1 CD22 BioID. Table S10. Brunello library sgRNA normalized read counts of NGI-1 drug modified screen (TMD8). Table S11. CRISPR screen score of NGI-1 drug modifier screen. Table S12. TMD8 Drug screen Excess HSA.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normalized Read Counts of CRISPR screens. Table S5. CRISPR screen score of essentiality screens. Table S6. Glycoproteomics after NGI-1 treatment. Table S7.HBL1 and TMD8 Phosphotyrosone Phosphoproteome (pYome). Table S8. TMD8 CD79A-BioID. Table S9. HBL1 CD22 BioID. Table S10. Brunello library sgRNA normalized read counts of NGI-1 drug modified screen (TMD8). Table S11. CRISPR screen score of NGI-1 drug modifier screen. Table S12. TMD8 Drug screen Excess HSA.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Supplemental Figure 1. IRF4-GFP knock-in reporter cell lines. Supplemental Figure 2. IRF4-GFP CRISPR screen in adult T-cell lymphoma and screen controls. Supplemental Figure 3. The OST is essential for DLBCL. Supplemental Figure 4. The role of the OST complex in radiation chimeras. Supplemental Figure 5. The B-cell receptor is glycosylated by the OST complex. Supplemental Figure 6. B-cell receptor deglycosylation leads to higher surface expression. Supplemental Figure 7. B-cell receptor deglycosylation leads to signaling changes in proximal BCR signaling components. Supplemental Figure 8. BCR deglycosylation leads to recruitment of CD22 on the cell surface to the BCR and signaling alterations in GCB DLBCL. Supplemental Figure 9. BCR internalization and My-T-BCR formation in glycosylation deficient cells. Supplemental Figure 10. NGI-1 synergizes with BTK and PI3K inhibitors.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Supplemental Figure 1. IRF4-GFP knock-in reporter cell lines. Supplemental Figure 2. IRF4-GFP CRISPR screen in adult T-cell lymphoma and screen controls. Supplemental Figure 3. The OST is essential for DLBCL. Supplemental Figure 4. The role of the OST complex in radiation chimeras. Supplemental Figure 5. The B-cell receptor is glycosylated by the OST complex. Supplemental Figure 6. B-cell receptor deglycosylation leads to higher surface expression. Supplemental Figure 7. B-cell receptor deglycosylation leads to signaling changes in proximal BCR signaling components. Supplemental Figure 8. BCR deglycosylation leads to recruitment of CD22 on the cell surface to the BCR and signaling alterations in GCB DLBCL. Supplemental Figure 9. BCR internalization and My-T-BCR formation in glycosylation deficient cells. Supplemental Figure 10. NGI-1 synergizes with BTK and PI3K inhibitors.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Supplemental Figure 1. IRF4-GFP knock-in reporter cell lines. Supplemental Figure 2. IRF4-GFP CRISPR screen in adult T-cell lymphoma and screen controls. Supplemental Figure 3. The OST is essential for DLBCL. Supplemental Figure 4. The role of the OST complex in radiation chimeras. Supplemental Figure 5. The B-cell receptor is glycosylated by the OST complex. Supplemental Figure 6. B-cell receptor deglycosylation leads to higher surface expression. Supplemental Figure 7. B-cell receptor deglycosylation leads to signaling changes in proximal BCR signaling components. Supplemental Figure 8. BCR deglycosylation leads to recruitment of CD22 on the cell surface to the BCR and signaling alterations in GCB DLBCL. Supplemental Figure 9. BCR internalization and My-T-BCR formation in glycosylation deficient cells. Supplemental Figure 10. NGI-1 synergizes with BTK and PI3K inhibitors.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Supplemental Figure 1. IRF4-GFP knock-in reporter cell lines. Supplemental Figure 2. IRF4-GFP CRISPR screen in adult T-cell lymphoma and screen controls. Supplemental Figure 3. The OST is essential for DLBCL. Supplemental Figure 4. The role of the OST complex in radiation chimeras. Supplemental Figure 5. The B-cell receptor is glycosylated by the OST complex. Supplemental Figure 6. B-cell receptor deglycosylation leads to higher surface expression. Supplemental Figure 7. B-cell receptor deglycosylation leads to signaling changes in proximal BCR signaling components. Supplemental Figure 8. BCR deglycosylation leads to recruitment of CD22 on the cell surface to the BCR and signaling alterations in GCB DLBCL. Supplemental Figure 9. BCR internalization and My-T-BCR formation in glycosylation deficient cells. Supplemental Figure 10. NGI-1 synergizes with BTK and PI3K inhibitors.
- Open Access
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Supplemental Figure 1. IRF4-GFP knock-in reporter cell lines. Supplemental Figure 2. IRF4-GFP CRISPR screen in adult T-cell lymphoma and screen controls. Supplemental Figure 3. The OST is essential for DLBCL. Supplemental Figure 4. The role of the OST complex in radiation chimeras. Supplemental Figure 5. The B-cell receptor is glycosylated by the OST complex. Supplemental Figure 6. B-cell receptor deglycosylation leads to higher surface expression. Supplemental Figure 7. B-cell receptor deglycosylation leads to signaling changes in proximal BCR signaling components. Supplemental Figure 8. BCR deglycosylation leads to recruitment of CD22 on the cell surface to the BCR and signaling alterations in GCB DLBCL. Supplemental Figure 9. BCR internalization and My-T-BCR formation in glycosylation deficient cells. Supplemental Figure 10. NGI-1 synergizes with BTK and PI3K inhibitors.
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Supplemental Figure 1. IRF4-GFP knock-in reporter cell lines. Supplemental Figure 2. IRF4-GFP CRISPR screen in adult T-cell lymphoma and screen controls. Supplemental Figure 3. The OST is essential for DLBCL. Supplemental Figure 4. The role of the OST complex in radiation chimeras. Supplemental Figure 5. The B-cell receptor is glycosylated by the OST complex. Supplemental Figure 6. B-cell receptor deglycosylation leads to higher surface expression. Supplemental Figure 7. B-cell receptor deglycosylation leads to signaling changes in proximal BCR signaling components. Supplemental Figure 8. BCR deglycosylation leads to recruitment of CD22 on the cell surface to the BCR and signaling alterations in GCB DLBCL. Supplemental Figure 9. BCR internalization and My-T-BCR formation in glycosylation deficient cells. Supplemental Figure 10. NGI-1 synergizes with BTK and PI3K inhibitors.
- Open Access
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normalized Read Counts of CRISPR screens. Table S5. CRISPR screen score of essentiality screens. Table S6. Glycoproteomics after NGI-1 treatment. Table S7.HBL1 and TMD8 Phosphotyrosone Phosphoproteome (pYome). Table S8. TMD8 CD79A-BioID. Table S9. HBL1 CD22 BioID. Table S10. Brunello library sgRNA normalized read counts of NGI-1 drug modified screen (TMD8). Table S11. CRISPR screen score of NGI-1 drug modifier screen. Table S12. TMD8 Drug screen Excess HSA.
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normalized Read Counts of CRISPR screens. Table S5. CRISPR screen score of essentiality screens. Table S6. Glycoproteomics after NGI-1 treatment. Table S7.HBL1 and TMD8 Phosphotyrosone Phosphoproteome (pYome). Table S8. TMD8 CD79A-BioID. Table S9. HBL1 CD22 BioID. Table S10. Brunello library sgRNA normalized read counts of NGI-1 drug modified screen (TMD8). Table S11. CRISPR screen score of NGI-1 drug modifier screen. Table S12. TMD8 Drug screen Excess HSA.
- Open Access
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Supplemental Figure 1. IRF4-GFP knock-in reporter cell lines. Supplemental Figure 2. IRF4-GFP CRISPR screen in adult T-cell lymphoma and screen controls. Supplemental Figure 3. The OST is essential for DLBCL. Supplemental Figure 4. The role of the OST complex in radiation chimeras. Supplemental Figure 5. The B-cell receptor is glycosylated by the OST complex. Supplemental Figure 6. B-cell receptor deglycosylation leads to higher surface expression. Supplemental Figure 7. B-cell receptor deglycosylation leads to signaling changes in proximal BCR signaling components. Supplemental Figure 8. BCR deglycosylation leads to recruitment of CD22 on the cell surface to the BCR and signaling alterations in GCB DLBCL. Supplemental Figure 9. BCR internalization and My-T-BCR formation in glycosylation deficient cells. Supplemental Figure 10. NGI-1 synergizes with BTK and PI3K inhibitors.
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Supplemental Figure 1. IRF4-GFP knock-in reporter cell lines. Supplemental Figure 2. IRF4-GFP CRISPR screen in adult T-cell lymphoma and screen controls. Supplemental Figure 3. The OST is essential for DLBCL. Supplemental Figure 4. The role of the OST complex in radiation chimeras. Supplemental Figure 5. The B-cell receptor is glycosylated by the OST complex. Supplemental Figure 6. B-cell receptor deglycosylation leads to higher surface expression. Supplemental Figure 7. B-cell receptor deglycosylation leads to signaling changes in proximal BCR signaling components. Supplemental Figure 8. BCR deglycosylation leads to recruitment of CD22 on the cell surface to the BCR and signaling alterations in GCB DLBCL. Supplemental Figure 9. BCR internalization and My-T-BCR formation in glycosylation deficient cells. Supplemental Figure 10. NGI-1 synergizes with BTK and PI3K inhibitors.
- Open Access
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normalized Read Counts of CRISPR screens. Table S5. CRISPR screen score of essentiality screens. Table S6. Glycoproteomics after NGI-1 treatment. Table S7.HBL1 and TMD8 Phosphotyrosone Phosphoproteome (pYome). Table S8. TMD8 CD79A-BioID. Table S9. HBL1 CD22 BioID. Table S10. Brunello library sgRNA normalized read counts of NGI-1 drug modified screen (TMD8). Table S11. CRISPR screen score of NGI-1 drug modifier screen. Table S12. TMD8 Drug screen Excess HSA.
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normalized Read Counts of CRISPR screens. Table S5. CRISPR screen score of essentiality screens. Table S6. Glycoproteomics after NGI-1 treatment. Table S7.HBL1 and TMD8 Phosphotyrosone Phosphoproteome (pYome). Table S8. TMD8 CD79A-BioID. Table S9. HBL1 CD22 BioID. Table S10. Brunello library sgRNA normalized read counts of NGI-1 drug modified screen (TMD8). Table S11. CRISPR screen score of NGI-1 drug modifier screen. Table S12. TMD8 Drug screen Excess HSA.